摘要
目的:基于对Lewis肺癌组织中VEGF-C蛋白及mRNA表达的影响,探讨康莱特注射液抗肿瘤转移的分子机制,为其临床应用提供理论疗效证据。方法:50只C57小鼠接种Lewis肺癌瘤株后,随机分为5组:模型组、CTX组、康莱特低剂量组、康莱特中剂量组、康莱特高剂量组。分别腹腔注射相应药物15d后处死,免疫组化法检测各组小鼠肺癌组织中VEGF-C蛋白的阳性表达,用RT-PCR检测VEGF-CmRNA的表达。结果:模型组、CTX组、康莱特低剂量组、康莱特中剂量组、康莱特高剂量组各组中VEGF-C蛋白的阳性表达率分别为:(9.02±0.63)、(3.85±0.27)、(5.23±0.19)、(3.22±0.08)、(2.02±0.06),各组VEGF-CmRNA/GAPDH比值分别为(2.42±0.08)、(2.17±0.06)、(1.75±0.02)、(0.67±0.05)、(0.46±0.03)。结论:抑制VEGF-C蛋白及mRNA的表达可能是康莱特注射液抗肿瘤转移的分子机制之一。
Objective：To study the mol-mechanisms of KLT injection anti-tumor metabasis, according to the effection that the KLT affect on the VEGF-C proteinum and mRNA of Lewis lung cancer tissue. Methods： The 50 C57 mice v-ere randomly divided into 5 groups after copied Lewis lung cancer model to them： the model group, the chemotherapy group, the LD KLT group, the MD KLT group and the HD KLT group, Sacrifice the mice after inject the diff-medicine to abdominal cavity for 15 days, the immunohistochemistry technique used to detect the expression of VEGF-C proteinum of lung cancer tissue, RT-PCR technique to detect the expression of VEGF-C mRNA, Results： the masc-expression rate of VEGF-C in every group is （9.02± 0.63）. （3.85± 0.27）. （5.23± 0.19）, （3.22± 0.08）. （2.02± 0.06） corresponding, the proportionality of gray scale of NF-kB/GAPDH in all groups separately is （2,42± 0.08）. （2.17± 0,06）. （1.75±0.02）. （0.67± 0.05）.（0.46± 0.03）.Conclusion： It＇ s maybe the one of the mol-mechanisms of KLT to restrain tumor＇ s metabasis by inhibiting the masc.-expression of VEGF-C and mRNA.
出处
《实用中西医结合临床》
2008年第1期5-6,共2页
Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine
基金
浙江省中医药管理局基金资助课题(No.2004c065)
